Gan to Kagaku Ryoho Cancer & Chemotherapy · Oct 2026
Personalized Dosing of Lenalidomide Based on Integrated Assessment of Renal Function and Frailty in Multiple Myeloma
By Takakuwa T, Ohta K, Tanada Y et al.
Determining the optimal initial dose of lenalidomide (Len) for the treatment of multiple myeloma (MM) remains challenging, particularly in elderly and frail patients. We propose the stratified adjusted frailty and excretion (SAFE) method, a dosing strategy that incorporates both renal function and frailty, and present a case illustrating its clinical utility. A 74-year-old woman was diagnosed with IgG-kappa MM after presenting with pancytopenia. Her medical history included liver cirrhosis, pulmonary fibrosis, and dementia with Lewy bodies, and her Eastern Cooperative Oncology Group performance status was 4, indicating poor general condition. Her creatinine clearance was 42.4 mL/min. Based on the SAFE method, treatment with daratumumab, Len, and dexamethasone was initiated with lenalidomide started at 5 mg once weekly. The regimen was well tolerated, allowing stepwise dose escalation. After 6 cycles, the patient achieved complete remission. Improvements in activities of daily living and cognitive function were also observed. The SAFE method provides a practical approach for individualizing the initial Len dose by integrating renal function and frailty assessments. This strategy may facilitate safe introduction of therapy in elderly and frail patients with MM.